Metaiodobenzylguanidine (MIBG) is an enzymatically stable synthetic analog of norepinephrine that when radiolabled with diagnostic ( 123 I) or therapeutic ( 131 I) isotopes has been shown to concentrate highly in sympathetically innervated tissues such as the heart and neuroendocrine tumors that possesses high levels of norepinephrine transporter (NET). As the transport of MIBG by NET is a saturable event, the specific activity of the preparation may have dramatic effects on both the efficacy and safety of the radiodiagnostic/ radiotherapeutic. Using a solid labeling approach (Ultratrace), noncarrier-added radiolabeled MIBG can be efficiently produced. In this study, specific activities of >1200 mCi/mmol for I exhibited similar tissue distribution to the carrier-added radiolabeled MIBG in all nontarget tissues. In tissues that express NETs, the higher the specific activity of the preparation the greater will be the radiopharmaceutical uptake. This was reflected by greater efficacy in the mouse neuroblastoma SK-N-BE(2c) xenograft model and less appreciable cardiovascular side-effects in dogs when the high-specific-activity radiopharmaceutical was used. The increased uptake and retention of Ultratrace 123/131 I-MIBG may translate into a superior diagnostic and therapeutic potential. Lastly, care must be taken when administering therapeutic doses of the current carrieradded 131 I-MIBG because of its potential to cause adverse cardiovascular side-effects, nausea, and vomiting.
I and >1600 mCi/mmol for 131 I have been achieved. A series of studies were performed to assess the impact of cold carrier MIBG on the tissue distribution of 123/131 I-MIBG in the conscious rat and on cardiovascular parameters in the conscious instrumented dog. The present series of studies demonstrated that the carrier-free Ultratrace MIBG radiolabeled with either 123 I or 131 I exhibited similar tissue distribution to the carrier-added radiolabeled MIBG in all nontarget tissues. In tissues that express NETs, the higher the specific activity of the preparation the greater will be the radiopharmaceutical uptake. This was reflected by greater efficacy in the mouse neuroblastoma SK-N-BE(2c) xenograft model and less appreciable cardiovascular side-effects in dogs when the high-specific-activity radiopharmaceutical was used. The increased uptake and retention of Ultratrace Introduction T argeted molecular radiotherapy is the logical extension of molecular diagnostic radionuclide imaging. Treatment success in cancer depends on sufficient upregulation of disease target, the specificity of the target, choice of the radionuclide, and a sufficient concentration delivered to and residence time at the target. 1 Metaiodobenzylguanidine (MIBG) is a synthetic analog of the biogenic amine, norepinephrine, and has been widely used in its radiolabeled forms (usually 131 I or 123 I) since the early 1980s for the diagnosis and, when labeled with iodine-131, radiotherapy of various neuroendocrine tumors such as neuroblastoma, pheochromocytoma, and carcinoid. Like norepinephrine, MIBG is concentrated in sympathomedullary tissues predominantly by an active uptake mechanism, the norepinephrine transporter (NET). [2] [3] [4] The NET is expressed on the surfaces of highly sympathetically innervated cells of normal tissue, such as the heart and adrenal glands, and is highly expressed in tumors of neural crest origin, such as neuroblastoma and pheochromocytoma. [2] [3] [4] This uptake and prolonged retention of MIBG within the intracellular 1 catecholamine storage vesicles constitute an ideal target/ mechanism to exploit for the detection and treatment of neuroendocrine tumors because it ensures an increased concentration and dwell time of the radiodiagnostic/ therapeutic in the tumor.
The current commercial methods to produce 123 I-and 131 I-MIBG utilize the copper-catalyzed isotope exchange reaction. This method requires 1-2 mg of nonradioactive MIBG, which must be present in 2000-fold molar excess to the radioactive sodium iodide ( 131 I or 123 I), coupled with heating the mixture to 1508C, to drive the halogen exchange to equilibrium. The radiolabled MIBG is subsequently separated by column chromatography. Although this is a simple synthesis, it precludes the ability to produce MIBG with high specific activity because of the inability to separate nonradiolabeled MIBG by column chromatography. Vaidyanathan and Zalutsky 5 developed two routes to synthesize high-specificactivity MIBG, in which the use of the halogen exchange reaction was avoided by using nonradiolabeled iodine for iodine (123 or 131). However, a time-consuming highperformance liquid chromatography purification is required. Hunter and Zhu 6 have demonstrated a more practical approach in the use of aryl-tin intermediates, where the benzylguanidine precursor is bound to a polystyrene-based resin through a di-butyltin linker. Radiolabeling is performed simply by heating 131 I-sodium iodide with an oxidizing agent and filtering off the radiolabeled MIBG. The intrinsic implication of this technique is that very highspecific-activity iodine-labeled radiopharmaceuticals can be rapidly produced with no other components in the solution, except the aqueous vehicle. This process offers a true ''carrier-free'' or ''noncarrier-added'' radiopharmaceutical preparation and thus avoids any potential competitive pharmacological effects of the carrier. Molecular Insight Pharmaceuticals, Inc., is developing this true ''carrier-free'' version of 
Materials and Methods

Radiopharmaceuticals
High-specific-activity 123/131 I-MIBG was produced by Molecular Insight Pharmaceuticals via a validated cGMP process, using the Ultratrace solid phase method. It was provided as a sterile frozen solution, with a high specific activity and in radioactive concentration. The Ultratrace process uses a solid polystyrene resin containing the covalently bound stannylbenzylguanidine precursor, which undergoes a 1:1 displacement reaction with iodine at room temperature. Briefly, the solid phase precursor is suspended in a dilute mixture of radioactive 123/131 I-sodium iodide, hydrogen peroxide, and acetic acid at 258C for 60 minutes. The oxidized 123/131 I-iodine reacts to disrupt the covalent bond between the tin and benzylguanidine precursor with radioiodine insertion at the meta position of the phenyl ring to form 123 g) were determined. Blood samples were also obtained at the time of sacrifice and weighed, and total radioactivity was determined. Tissue samples were counted along with aliquots of the injected dose to correct for radioactive decay and to calculate %ID contained in each sample. The %ID/g per tissue was calculated by converting the decay-corrected counts per minute to the percent dose or the amount of radioactivity in nCi and then dividing by the weight of the tissue or organ sample.
Cardiovascular effects in conscious dogs
Four (4) male and 4 female beagle dogs were surgically implanted with telemetry units to permit the assessment of arterial pressure and heart rate in the conscious free-roaming state. A gel-filled pressure transducer (for blood pressure measurements) was inserted into the left femoral artery and secured appropriately. Two electrocardiogram (ECG) leads (one positive and one negative) were tunneled through the subcutaneous tissue to the left ventrolateral thoracic region (positive lead) and on to the right ventral chest region, cranial to the manubrium of the sternum and to the right of the midline (negative lead). Upon completion of a 3-week postsurgical recovery and acclimation period, each dog was intravenously (i.v.) administered saline followed by MIBG in ascending doses of 0.03, 0.3, 1, and 3 mg/kg, i.v., at 30-minute intervals and the effects on arterial pressure, heart rate, and behavior were continuously monitored. The doses were chosen to encompass the range of total MIBG administered in human-equivalent therapeutic preparations of 131 I-MIBG.
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I-MIBG therapy study
Human neuroblastoma xenografts were established in CD/1 nu/nu athymic mice by using the method described by Rutgers et al. 7 A suspension containing 3Â10 6 freshly harvested SK-N-BE(2c) cells was delivered by intrasplenic injection. When palpable hepatic and splenic tumors developed, 2-3-mm fragments were placed subcutaneously into the subcostal flank of new nescient mice. When tumors reached an average volume of *400 mm 3 , animals were randomly assigned to one of the treatment groups. Animals were divided into the following 7 groups (N ¼ 8-10 mice per group): saline, carrier-added 131 I-MIBG or noncarrier-added Ultratrace 131 I-MIBG at 8.1, 24.3, and 81 mCi/m 2 (2.7, 8.1, and 27 mCi/kg). Each animal was administered the test sample i.v in a volume of 0.1 mL, using the schedule outlined above, for *10 seconds. Tumor dimensions were measured twice weekly with digital calipers and tumor volumes were calculated with the following formula: (width 2 Âlength)/2. Mice were followed until tumor volumes reached the maximal allowable size per IACUC guidelines of 1500 mm 3 .
Carrier-added 131 I-MIBG, manufactured via the halogen exchange method, was purchased from Amersham Biosciences. It had a specific activity of 8.25 mCi/mmol at the time of injection, whereas the Ultratrace 131 I-MIBG (ultra) had a specific activity of 1283 mCi/mmol (155-fold increase in specific activity).
Data analysis
All values were decay corrected to the time of injection and are expressed as the mean AE standard deviation or standard error of the mean. To assess differences between the groups, statistical analyses consisting of a one-way analysis of the variance and, where appropriate, Student's unpaired t-test (DF ¼ N À 1; two-tailed probability) were performed. Differences were considered significant when p < 0.05.
The pharmacokinetics of 123/131 I-MIBG was analyzed by WinNonlin 4.1 (Pharsight). The blood and tissue concentrationtime data were computed by a noncompartment method and PK parameters (C max , AUC, and MRT) were generated. Total organ clearance (CL) was calculated from the following equation: CL ¼ dose/AUC. Steady-state volume of distribution (V ss ) was calculated as follows: V ss ¼ MRTÂCL.
Results
Comparison of 123 I-MIBG manufactured via the Ultratrace or the halogen exchange method
A study was conducted in rats to investigate the impact of cold carrier (carrier added) on the tissue distribution of 123 I-MIBG. This was accomplished by comparing the highspecific-activity (1283 mCi/mmol), noncarrier-added 123 I-MIBG prepared via the Ultratrace method to the currently used halogen exchange method to produce 123 I-MIBG with a specific activity of 8.25 mCi/mmol.
Both preparations were cleared from the blood in a similar manner, and at 72 hours postinjection, blood levels of both preparations were below the limits of detection (Fig. 1) . The terminal half-life for the carrier-added preparation and the Ultratrace preparation did not differ (15 and 18 hours, respectively). There was no significant difference in the C max levels when comparing the preparations in individual tissues. Total radioactivity tissue exposure was determined using AUC 0-inf . A 1.8 times greater exposure was observed in the heart and lung in the Ultratrace 123 I-MIBG-treated animals when compared with the carrier-added preparation. Radioactive exposure in the bone marrow tended to be lower (approximately half ) in the Ultratrace group when compared with the carrier-added preparation (Fig. 2) .
FIG. 1. Blood clearance of
123 I-MIBG prepared using the Ultratrace or the carrier-added method in the conscious rat administered 40 mCi/kg intravenously. The blood concentrations are expressed as the mean AE standard deviation in nCi/mL decay corrected to the time of injection for 4 rats each per time point. The specific activity of the Ultratrace 123 I-MIBG was 1283 mCi/mmol and of the carrier-added 123 I-MIBG was 8.25 mCi/mmol, which resulted in MIBG doses of 1.8 and 0.01 mg/kg, respectively. MIBG, metaiodobenzylguanidine.
FIG. 2. Tissue exposure of
123 I-MIBG prepared using the Ultratrace or the carrier-added method in the conscious rat administered 40 mCi/kg intravenously. The AUC 0-inf is expressed as the mean tissue exposure in the conscious rat. Each histogram is the mean exposure calculated using six time points with 4 rats per time point. The specific activity of the Ultratrace 123 I-MIBG was 1283 mCi/mmol and of the carrier-added 123 I-MIBG was 8.25 mCi/mmol, which resulted in MIBG doses of 1.8 and 0.01 mg/kg, respectively. MIBG, metaiodobenzylguanidine. The tissue distributions of 131 I-MIBG prepared using (1) the Ultratrace method and (2) the iodine exchange, carrier added, method (CIS-US 131 I-MIBG) were assessed in separate groups of 4 rats each at six time points through 72 hours postinjection. In the present study, 131 I-MIBG was i.v. administered at 40 mCi/kg (specific activity: Ultratrace >1600 mCi/mmol and Cis 1 mCi/mmol). Tables 1 and 2 show the tissue distributions of 131 I-MIBG prepared using the Ultratrace method versus the CIS-US product prepared using the halogen exchange method. Both 131 I-MIBG preparations were cleared from the blood in a similar manner. After reaching C max (the first time point), blood concentrations readily declined, with similar residence times of 22. 2 I-MIBG is slowly cleared in rats. Blood exposure (AUC 0-inf ) was similar for both the Ultratrace (286 hoursÁnCi/mL) and the CIS-US (323 [hoursÁnCi]/mL) preparations. Mean volume of distribution at steady state (V ss ) ranged from 3.1 to 2.4 L/kg for the Ultratrace and the CIS-US groups, respectively. Thus, in a 0.3-kg male rat, V ss would be *1 L, which is >100% of body weight (assuming that 1 L is equal to 1 kg). This indicates that 131 I-MIBG is highly distributed into deep tissue compartments.
As anticipated, because of the mechanism of action of MIBG, uptake and exposure were greatest in the heart. 8 After reaching C max at the first time point, heart concentrations declined with mean residence times of 12.1 and 11.7 hours for the Ultratrace The published literature indicates that the bone marrow is the dose-limiting organ for the carrier-added 131 I-MIBG.
9,10
After reaching C max , at the first time point (18 and 21 nCi/g for the Ultratrace and the CIS, respectively), marrow concentrations declined, with similar mean residence times of 12.3 and 9. 
I-MIBG and the cold carrier MIBG in the conscious rat
To study the implications of the cold carrier MIBG when therapeutic doses of 131 I-MIBG are administered, a tissue distribution study was conducted in conscious rats, wherein the specific activity of the test preparations was adjusted to mimic the amount of cold carrier that would be present at therapeutic doses in the range of 5-10 mCi/kg by using the specific activity of the current commercially available Izotop and the previously available Michigan 131 I-MIBG products. In the present study, rats were administered 40 mCi/kg (240 mCi/m 2 ) Ultratrace fortified with cold MIBG to mimic doses of 185 and 370 mCi/m 2 (5 and 10 mCi/kg) in man. In the noncarrier-added Ultratrace group, because of the high specific activity, the total amount of MIBG administered was below the limits of quantification. The fortified Ultratrace 131 I-MIBG showed comparable blood pharmacokinetics when compared with the Ultratrace 131 I-MIBG (Fig. 4) . The radiolabel was detected at varying levels in all tissues examined, which decreased readily over time. No difference in tissue distribution was noted with the exception of the heart between 46.5 and 93 mg/mCi (5 and 10 mCi cold carrier mimic) carrier 131 I-MIBG. Increasing amounts of the cold carrier MIBG resulted in decreased uptake of 131 I-MIBG in the heart (Fig. 4) . Notably, when compared with the noncarrier-added Ultratrace 131 I-MIBG, both preparations demonstrated a significant ( p < 0.005) reduction in exposure (AUC) to 131 I-MIBG in the heart. At 6 hours postinjection, concentrations of 115.05 AE 33.71, 28.40 AE 3.67, and 22.34 AE 4.00 nCi/g were determined for the Ultratrace 131 I-MIBG, the Ultratrace 131 I-MIBG plus 46.5 mg/mCi, and the Ultratrace 131 I-MIBG plus 93 mg/mCi, respectively.
The decrease in uptake in the heart with low specific activity was anticipated because the heart is a highly innervated tissue with high expression of the norepinephrine Analysis was performed using the mean AE standard deviation for 4 rats at six time points. CIS-US (specific activity: 1 mCi/mmol) and Ultratrace 131 I-MIBG (specific activity: >1600 mCi/mmol) at 40 mCi/kg were studied in separate groups of 4 rats per time point with six time points through 72 hours postinjection.
MIBG, metaiodobenzylguanidine.
ULTRATRACE 123/131 I-MIBGuptake-1 transporter. Interestingly, a tendency toward a dose-related increase in 131 I-MIBG uptake in the presence of increasing amounts of the cold carrier MIBG was observed in the bone marrow (Figs. 4 and 5) .
Impact of MIBG on the cardiovascular system in the conscious dog
A study was performed to assess the impact of the cold carrier MIBG on the cardiovascular system (arterial pressure, heart rate, and ECG) in conscious telemeterized dogs. The doses were chosen to determine the amount of cold carrier commonly observed in the current commercially available 131 I-MIBG therapeutic products. At a dose of 370 mCi/m 2 , the resultant amount of MIBG delivered by using the Ultratrace 131 I-MIBG was 3 mg/kg, whereas by using the Izotop and University of Michigan products *600-1000 mg/kg was delivered.
Treatment with MIBG at doses up to 3000 mg/kg had no adverse effect on mortality, clinical, cageside, or postinjection observations, body weights, body weight changes, body temperature, or QT values.
A dose-dependant increase in arterial pressure concomitant with a reflex bradycardia was observed in all animals, with the reflex bradycardia maximized at 1 mg/kg, i.v. At 3 mg/kg, i.v., the duration of action was >20 minutes. MIBG at 30, 300, 1000, and 3000 mg/kg, i.v., elicited dose-related increases in mean arterial pressure of 0%, 13%, 32%, and 45%, respectively, from the baseline value of 108 AE 4 mmHg. A reflex bradycardia was observed, wherein heart rate decreased by 8%, 39%, 50%, and 43%, respectively, from the baseline value of 111 AE 4 bpm (Fig. 6) .
All ECGs were within normal limits following bolus intravenous administration of MIBG at doses of 30 and 3000 mg/kg. , animals were randomly assigned to one of the 7 treatment groups. There were no significant differences in the average starting tumor volume in any of the treatment groups. Saline treatment resulted in a linear growth rate over 15 days at which point the animals were euthanized because of tumor size of >1500 mm (Table 4 and Fig. 7 ). At 45 days after the administration of 81 mCi/m 2 (27 mCi/ kg) Ultratrace 131 I-MIBG, the tumor size increased fourfold above baseline when compared with the same administered radioactive dose of the carrier-added 131 I-MIBG, wherein a fourfold increase in growth rate was observed at 28 days post-treatment.
Discussion
Treatment success of radiopharmaceuticals depends on sufficient upregulation of the receptor or enzyme in the disease, the specificity of the target, choice of the radionuclide, and a sufficient concentration delivered to and retained at the target. 1 The selective targeted delivery of beta emitters to the tumor results in the formation of oxygen-derived free radicals, which interact among themselves to produce additional free radicals. The production of oxygen-derived free radicals is the primary mechanism by which beta radiation induces biological damage at lower radiation absorbed doses to the tumor. 11, 12 Because of their rapid metabolic rate, tumor cells have developed several defense and repair mechanisms to deal with the generation of free radicals, the antioxidants being the primary mechanism. When an appropriate dose of beta radiation is administered, this primary defense mechanism can be overcome, resulting in the degradation of the damaged target proteins that culminates with apoptosis of the irreversibly damaged cells. 13, 14 Iodine-131 is a desirable isotope for radiotherapy because it possesses both gamma energy for the detection of avid lesions and beta energy to induce tumor cell apoptosis. The targeting moiety described in this article, MIBG coupled with iodine-131, was chosen for the treatment of neuroendocrine tumors because MIBG is an enzymatically stable analog of norepinephrine that has been shown to concentrate in highly sympathetically innervated tissues such as the heart and neuroendocrine tumors. 15 As the NET and presynaptic storage granules, as well as chromaffin granules, are saturable, the specific activity of the preparation may have dramatic effects on both the safety and efficacy of the radiodiagnostic/radiotherapeutic. Using the Ultratrace method, which removes virtually all of the nonradiolabeled MIBG, we were able to achieve specific activities of >1200 mCi/mmol for 123 I-MIBG and 1600 mCi/mmol for 131 I-MIBG. Andreview, a commercially available preparation of 123 I-MIBG, has a specific activity of *1 mCi/mmol, whereas radiotherapeutic preparations of 131 I-MIBG have specific activities between 1 and 10 mCi/mmol.
The working hypothesis of the present study is that the Ultratrace MIBG will have a similar tissue distribution to the commercially available preparations in tissues with low sympathetic innervation but have superior uptake and retention in those that are highly innervated. To test this hypothesis, the tissue distributions of the Ultratrace 123/131 I-MIBG and the carrier-added 123/131 I-MIBG were studied. In the present study, the Ultratrace 123 I-MIBG and the carrier-added 123 I-MIBG showed similar tissue distribution and pharmacokinetics of radiolabeled compound in most tissues. For the amount of carrier examined here, in the carrier-added preparation there was a 300-1000-fold increase in the transporter exposure to MIBG total mass when compared with the Ultratrace preparation, resulting in, as anticipated, 50% less agonist exposure to the heart compared with the carrier-added preparation (Figs. 2 and 3) . These results are in agreement with those of Verberne et al., 8 who demonstrated that decreasing the specific activity from 5.4 to 1.1 mCi/mmol resulted in a decrease of *20% in cardiac radioactive uptake. In addition, the present study assessed the impact of MIBG on the cardiovascular system and demonstrated that i.v. administered MIBG elicited a doserelated increase in arterial pressure concomitant with a reflex bradycardia in the normal canine. These results clearly show that the amount of cold carrier administered not only will have an impact on ability to accurately study the sympathetic innervation of the diseased heart but also may have cardiovascular safety implications for increase in blood pressure. Further, these data are consistent with the hypothesis that MIBG tissue uptake is an active process and that the cold carrier MIBG competes with 123 I-MIBG for target binding.
The impact of the cold carrier MIBG, administered at therapeutic levels, on tissue distribution was studied in normal rats. In the present study, the Ultratrace 131 I-MIBG was fortified with unlabeled MIBG to mimic the total amount of the cold carrier MIBG in doses of 5 or 10 mCi/kg products currently administered to patients. The amount of MIBG present at these levels using the Ultratrace 
